Immunohistochemical detection of apoptotic markers in gastric cancer

Oncology Research

Volumn 15, Issue 9, 2005, Pages 441-444

  Smith, Laura ^a   Berrieman, Helen K ^a   O'Kane, Sara L ^a   Campbell, Anne ^b   Maraveyas, Anthony ^a   Cawkwell, Lynn ^a,c  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL ROYAL INFIRMARY   (United Kingdom)

^c CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Gastric cancer; Immunohistochemistry; Stomach

Indexed keywords

BIM PROTEIN; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN P53; APOPTOSIS REGULATORY PROTEIN; BAD PROTEIN, HUMAN; BAK1 PROTEIN, HUMAN; BCL 2 BINDING PROTEIN, BIM; BCL-2-BINDING PROTEIN, BIM; MEMBRANE PROTEIN; ONCOPROTEIN; PROTEIN BCL X; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; TREATMENT RESPONSE; COMPARATIVE STUDY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR;

AGED; AGED, 80 AND OVER; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645816749     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504005776568246     Document Type: Article

References (16)

1. Reed, J. C. Mechanisms of apoptosis avoidance in cancer. Curr. Opin. Oncol. 11:68-75; 1999.
2. Sionov, R. V.; Haupt, Y. The cellular response to p53: Tthe decision between life and death. Oncogene 18:6145-6157; 1999.
3. Lee, H. K.; Lee, H. S.; Yang, H. K.; Kim, W. H.; Lee, K. U.; Choe, K. J.; Kim, J. P. Prognostic significance of Bcl-2 and p53 expression in gastric cancer. Int. J. Colorectal Dis. 18:518-525; 2003.
4. Nabeya, Y.; Loganzo, Jr., F.; Maslak, P.; Lai, L.; de Oliveira, A. R.; Schwartz, G. K.; Blundell, M. L.; Altorki, N. K.; Kelsen, D. P.; Albino, A. P. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int. J. Cancer 64:37-46; 1995.
5. Nakata, B.; Muguruma, K.; Hirakawa, K.; Chung, Y. S.; Yamashita, Y.; Inoue, T.; Matsuoka, T.; Onoda, N.; Kato, Y.; Sowa, M. Predictive value of Bcl-2 and Bax protein expression for chemotherapeutic effect in gastric cancer. A pilot study. Oncology 55:543-547; 1998.
6. Giatromanolaki, A.; Stathopoulos, G. P.; Koukourakis, M. I.; Rigatos, S.; Vrettou, E.; Kittas, C.; Fountzilas, G.; Sivridis, E. Angiogenesis and apoptosis-related protein (p53, bcl-2, and bax) expression versus response of gastric adenocarcinomas to paclitaxel and carboplatin chemotherapy. Am. J. Clin. Oncol. 24:222-226; 2001.
7. Cawkwell, L.; Gray, S.; Murgatroyd, H.; Sutherland, F.; Haine, L.; Longfellow, M.; O'Loughlin, S.; Cross, D.; Kronborg, O.; Fenger, C.; Mapstone, N.; Dixon, M.; Quirke, P. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 45:409-415; 1999.
8. Berrieman, H. K.; Smith, L.; O'Kane, S. L.; Campbell, A.; Lind, M. J.; Cawkwell, L. Expression of BCL-2-family proteins differs between non-small cell lung cancer subtypes. Cancer 103:1415-1419; 2005.
9. Victorzon, M.; Nordling, S.; Haglund, C.; Lundin, J.; Roberts, P. J. Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur. J. Cancer 32A: 215-220; 1996.
10. Liu, X. P.; Tsushimi, K.; Tsushimi, M.; Kawauchi, S.; Oga, A.; Furuya, T.; Sasaki, K. Expression of p21WAF1/CIP1 and p53 proteins in gastric carcinoma: Its relationships with cell proliferation activity and prognosis. Cancer Lett. 170:183-189; 2001.
11. Rajnakova, A.; Moochhala, S.; Goh, P. M.; Ngoi, S. Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett. 172:177-185; 2001.
12. Kikuyama, S.; Inada, T.; Shimizu, K.; Miyakita, M.; Ogata, Y. p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer. Anticancer Res. 21: 2149-2153; 2001.
13. Kondo, S.; Shinomura, Y.; Kanayama, S.; Higashimoto, Y.; Miyagawa, J. I.; Minami, T.; Kiyohara, T.; Zushi, S.; Kitamura, S.; Isozaki, K.; Matsuzawa, Y. Over-expression of bcl-xL gene in human gastric adenomas and carcinomas. Int. J. Cancer 68:727-730; 1996.
14. Nardone, G.; Rocco, A.; Vaira, D.; Staibano, S.; Budillon, A.; Tatangelo, F.; Sciulli, M. G.; Perna, F.; Salvatore, G.; Di Benedetto, M.; De Rosa, G.; Patrignani, P. Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: A molecular pathway of H pylori-related gastric carcinogenesis. J. Pathol. 202:305-312; 2004.
15. Liu, H. F.; Liu, W. W.; Fang, D. C.; Men, R. P. Expression and significance of proapoptotic gene Bax in gastric carcinoma. World J. Gastroenterol. 5:15-17; 1999.
16. Krajewska, M.; Fenoglio-Preiser, C. M.; Krajewski, S.; Song, K.; Macdonald, J. S.; Stemmerman, G.; Reed, J. C. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am. J. Pathol. 149: 1449-1457; 1996.